Core Viewpoint - Green Leaf Pharmaceutical (02186) has seen a nearly 3% increase in stock price, attributed to the successful inclusion of five new products in the National Medical Insurance Drug List for 2025 and the Commercial Health Insurance Innovative Drug List for 2025 [1] Group 1: Product Inclusion - Five new products from Green Leaf Pharmaceutical have been successfully included in the National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List for 2025 [1] - The new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) which are newly included in the National Medical Insurance Drug List [1] - Zanbija (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug List [1] - Baituo Wei® (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) have successfully renewed their contracts and continue to be included in the National Medical Insurance Drug List [1]

Core Insights - Green Leaf Pharmaceutical (02186) announced that five new products have been successfully included in the National Medical Insurance Drug List (2025) and the Commercial Health Insurance Innovative Drug List (2025) [1] Group 1: New Product Inclusion - The five new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug List [1] - Zanbija (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug List [1] - Baituowei (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) have successfully renewed their contracts and continue to be included in the National Medical Insurance Drug List [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) announced the successful inclusion of five new products in the National Medical Insurance Drug List (2025) and the Commercial Health Insurance Innovative Drug List (2025) [1] Group 1: New Product Inclusion - The five new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug List - Zanbija (Injectable Lurbinectedin) is successfully included in the Commercial Health Insurance Innovative Drug List - Baituo Wei (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug List [1][1][1] Group 2: Strategic Importance - The company believes that the synergy between medical insurance and commercial insurance is a significant measure to support the high-quality development of innovative drugs, promoting basic healthcare and innovation [1] - The inclusion of these five products through multiple access pathways into a multi-tiered medical security system will enhance drug accessibility for patients in related disease areas, effectively reducing their treatment burden [1][1] - This strategic move is expected to accelerate market penetration and coverage of these products, laying a solid foundation for their long-term high-quality growth [1][1]